Liminal BioSciences Inc. (https://liminalbiosciences.com) is a global biotechnology company that specialises in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. We focus specifically on developing solutions for rare and orphan diseases. Liminal BioSciences operates on an integrated basis from our three talent hubs in Laval, Quebec, Canada, Cambridge, UK and Rockville, Maryland, USA. Our common shares are listed for trading on the Toronto Stock Exchange (Symbol:LMNL).



Contact Information
Liminal BioSciences Inc.
[email protected]
+1.450.781.0115 

Latest

Sep 26, 2023, 08:00 ET LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

LAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /CNW/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously...

Sep 19, 2023, 16:22 ET LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

LAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of...

Sep 15, 2023, 11:29 ET LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved...

Sep 12, 2023, 07:45 ET LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

LAVAL, QC and CAMBRIDGE, England, Sept. 12, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule ...

Aug 16, 2023, 16:46 ET LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP

LAVAL, QC and CAMBRIDGE, England, Aug. 16, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice...

Aug 08, 2023, 16:05 ET Liminal BioSciences Reports Second Quarter Financial Results 2023

Provided R&D update on GPCR-targeted pipeline, including nomination of lead candidate for OXER1 antagonist program Closed June 30, 2023 with over CAD 19 million cash on hand, expecting to provide...

Jul 12, 2023, 07:30 ET Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP

Liminal BioSciences minority shareholders to receive US$8.50 in cash per share in "go private" transaction LAVAL, QC, CAMBRIDGE, England, and TORONTO, July 12, 2023 /CNW/ - Liminal BioSciences Inc....

Jun 05, 2023, 16:05 ET Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of ...

Jun 02, 2023, 08:00 ET Liminal BioSciences Provides R&D Update

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseases Advancement of clinical trial application (CTA)...

May 09, 2023, 16:05 ET Liminal BioSciences Reports First Quarter Financial Results 2023

GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023 Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide...

May 08, 2023, 08:00 ET The Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction Proposal

LAVAL, QC and CAMBRIDGE, England, May 8, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), re-confirms that the board of directors of the Company has...

Apr 05, 2023, 07:43 ET Liminal Biosciences Confirms Receipt of Unsolicited Non-Binding Transaction Proposal

LAVAL, QC and CAMBRIDGE, England, April 5, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), confirms that following close of markets on April 4, 2023,...

Mar 15, 2023, 16:05 ET Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery program aiming for the development of a...

Mar 13, 2023, 16:05 ET Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter...

Feb 15, 2023, 16:05 ET Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement

LAVAL, QC, Feb. 15, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from The Nasdaq Stock Market LLC...

Jan 26, 2023, 16:05 ET Liminal BioSciences Announces Reverse Stock Split

LAVAL, QC and CAMBRIDGE, England, Jan. 26, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued and...

Jan 19, 2023, 16:05 ET Liminal BioSciences to Present at BIO CEO & Investor Conference

LAVAL, QC and CAMBRIDGE, England, Jan. 19, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at...

Jan 06, 2023, 16:05 ET Liminal BioSciences Announces Priorities For 2023

Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024. Plans to divest its remaining non-core assets, to further extend runway. Nominated...

Nov 25, 2022, 08:00 ET Liminal BioSciences Announces Holding of Special Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England, Nov. 25, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it will be holding a virtual special meeting...

Nov 09, 2022, 16:05 ET Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of $33.1 million Net loss from continuing...

Nov 08, 2022, 07:00 ET Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022

LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third...

Sep 01, 2022, 16:15 ET Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market

LAVAL, QC and CAMBRIDGE, England, Sept. 1, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation from the Listing ...

Aug 29, 2022, 07:05 ET Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, QC and CAMBRIDGE, England, Aug. 29, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced that ...

Aug 25, 2022, 07:05 ET Liminal BioSciences Announces Termination of Legacy CDMO Contract

Termination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAVAL, QC and CAMBRIDGE, ENGLAND, Aug....

Aug 09, 2022, 17:07 ET Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE